Effectiveness of Rhenium(I)-diselenoether Low Doses in a Triple-negative Breast Cancer Chicken Embryo Model

Area of Science:

• Oncology
• Materials Science
• Pharmacology

Background:

• Rhenium(I)-diselenoether (Re-diSe) is a novel anticancer agent.
• Previous studies showed Re-diSe inhibited cancer cells and tumors, but with conflicting results in different models.
• This study aimed to validate Re-diSe efficacy in a specific breast cancer model.

Purpose of the Study:

• To evaluate the anticancer efficacy of Re-diSe in a transplanted MDA-MB-231 breast tumor model using the chicken chorioallantoic membrane (CAM) assay.
• To investigate dose-dependent effects of Re-diSe on tumor growth and characteristics.
• To clarify discrepancies in Re-diSe's anti-tumor activity observed in previous studies.

Main Methods:

• MDA-MB-231 cancer cells were xenografted onto chicken chorioallantoic membranes.
• Daily administration of Re-diSe at 0.1, 1, and 10 mg/kg for nine days.
• Tumor weight, histological analysis, and inflammatory cell infiltration were assessed.

Main Results:

• A low dose of 0.1 mg/kg significantly reduced tumor weights.
• The 1 mg/kg dose increased inflammation but did not significantly alter tumor weight compared to the 0.1 mg/kg dose.
• The 10 mg/kg dose eliminated visible tumors in 6/11 embryos, showing extensive necrosis and inflammatory cell infiltration.

Conclusions:

• Re-diSe demonstrated anticancer efficacy at a low dose (0.1 mg/kg) in this model.
• The higher dose (10 mg/kg) may exert anti-tumor effects through immune-mediated mechanisms.
• Re-diSe is confirmed as an effective anticancer agent with potential for further development.